Serina Therapeutics (SER) Amortization of Deferred Charges (2019 - 2025)

Serina Therapeutics has reported Amortization of Deferred Charges for 7 years, with the latest figure at $58000.0 in Q4 2025.

• Quarterly Amortization of Deferred Charges rose 625.0% year-over-year to $58000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $58000.0 (down 83.19% YoY) and the FY2025 annual result came in at $58000.0, down 83.19% from the prior year.
• Amortization of Deferred Charges grew to $58000.0 in Q4 2025 per SER's latest filing, from $8000.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $1.1 million in Q1 2023 and troughed at -$2.0 million in Q3 2023.
• A 5-year average of $290875.0 and a median of $288500.0 in 2021 frame the typical range for Amortization of Deferred Charges.
• The sharpest annual moves came in 2023 and 2025: Amortization of Deferred Charges plunged 328.18% in 2023, then surged 625.0% in 2025.
• Over 5 years, Amortization of Deferred Charges stood at $294000.0 in 2021, then surged by 211.56% to $916000.0 in 2022, then plunged by 315.72% to -$2.0 million in 2023, then soared by 100.4% to $8000.0 in 2024, then soared by 625.0% to $58000.0 in 2025.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $58000.0, $8000.0, and $8000.0 for Q4 2025, Q4 2024, and Q3 2024 respectively.